Date published: 2026-5-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

KRAP Inhibitors

KRAP inhibitors belong to a unique class of chemical compounds that specifically target and modulate the activity of Kinase-Related Protein (KRAP), a protein intimately involved in various cellular processes. KRAP, also known as DIAPH3 (Diaphanous-Related Formin-3), plays a pivotal role in the regulation of cell morphology, motility, and cytoskeletal organization. KRAP inhibitors interact with the protein to affect its functionality, mediating essential intracellular events that are crucial for maintaining cellular integrity and function. These inhibitors have been meticulously designed and synthesized to achieve selective and potent inhibition of KRAP, ensuring that the molecular mechanisms associated with the protein can be carefully studied and elucidated. Understanding the nuanced interactions and outcomes of KRAP inhibition allows for a deeper exploration of cellular processes, providing valuable insights into cell biology and molecular regulation.

The discovery and development of KRAP inhibitors has propelled the field of molecular biology, enabling researchers to delve deeper into the realms of cellular mechanisms. They serve as powerful tools for scientific exploration, offering a window into the complex world of protein kinases and their regulatory roles within cells. Their precise action allows for a more accurate examination of KRAP's involvement in cellular pathways, ensuring a focused approach in uncovering the underlying molecular narratives. By modulating the activity of KRAP, these inhibitors help unveil the intricacies of cellular dynamics, fostering an enriched understanding that bolsters the scientific inquiry into the vast landscape of cell biology and protein regulation.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits BCR-ABL kinase, used in chronic myeloid leukemia (CML) by blocking the abnormal signaling pathway.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Targets RAF kinase and VEGFR, used to inhibit angiogenesis and tumor growth in renal and hepatocellular carcinoma.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Inhibits EGFR kinase, used in non-small cell lung cancer (NSCLC) by blocking cell growth and proliferation.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dual SRC and BCR-ABL kinase inhibitor, effective against CML and certain types of leukemia.

Lapatinib ditosylate

388082-78-8sc-202205B
sc-202205
sc-202205A
5 mg
10 mg
25 mg
$49.00
$77.00
$117.00
15
(1)

Targets EGFR and HER2 kinases, employed in HER2-positive breast cancer to impede cell growth.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Inhibits multiple receptor tyrosine kinases (RTKs) including VEGFR, used for renal cell carcinoma and GISTs.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$131.00
$651.00
7
(1)

Inhibits mTOR kinase, employed as an immunosuppressant and for certain types of cancer.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1 and JAK2 kinase inhibitor, used for myelofibrosis and polycythemia vera.

BIBF1120

656247-17-5sc-364433
sc-364433A
5 mg
10 mg
$184.00
$321.00
2
(0)

Targets multiple kinases including VEGFR, used for idiopathic pulmonary fibrosis (IPF) to reduce fibrotic tissue formation.

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$175.00
$983.00
2
(1)

Potent BCR-ABL inhibitor, approved for CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).